| HOME >> MEDICINE >> TECHNOLOGY |
99Capital in excess of par value
1,354,2321,327,942Accumulated other comprehensive income
9681,025Accumulated deficit
(1,264,547)(1,226,609)Total stockholders' equity
90,662102,367Total liabilities and stockholders' equity
$
521,225$
575,518(1) The consolidated balance sheet at December 31, 2009 has been derived from the audited financial statements at that date but does not include all of the information and notes required by generally accepted accounting principles in the United States for complete financial statements. NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share information)(Unaudited)Three Months EndedTwelve Months EndedDecember 31,December 31,2010200920102009Revenue:Product sales and royalties
$ 12,699$ 10,832$ 34,667$
35,288License, collaboration and other
32,61528,177124,37236,643Total revenue
45,31439,009159,03971,931Operating costs and expenses:Cost of goods sold
10,2378,80925,66730,948Research and development
31,45524,713108,06595,109General and administrative
11,58510,98240,98641,006Impairment of long-lived assets
12,576-12,576-Total operating costs and expenses
65,85344,504187,294167,063Loss from operations
(20,539)(5,495)(28,255)(95,132)Non-operating income (expense):Interest income
3205281,5453,688Interest expense
(2,488)(2,963)(11,174)(12,176)Other income, net
391480827848Total non-operating expense
(1,777)(1,955)(8,802)(7,640)Loss before provision (benefit) for income taxes
(22,316)(7,450)(37,057)(102,772)Provision (benefit) for income taxes
264226881(253)Net loss
$ (22,580)$ (7,676)$ (37,938)$ (102,519)Basic and diluted net loss per share
$
(0.24)$ (0.08)$
(0.40)$
(1.11)Weighted average shares outstanding used incomputing basic and diluted net loss pershare
94,39893,21994,07992,772NEKTAR THERA
'/>"/>
| SOURCE Nektar Therapeutics Copyright©2010 PR Newswire. All rights reserved |